Analyst Jonathan Eckard is focused on the Healthcare sector with 54 price targets and ratings documented since 2012 spanning on 3 stocks. Previously, Jonathan Eckard worked at BARCLAYS, CITI. Analyst's average stock valuation to be materialised ratio is 67.31% with an average time for price targets to be met of 548.33 days.
Most recent stock forecast was given on ALKS, Alkermes plc at 29-Jul-2016.
Jonathan Eckard best performing recommendations are on ICPT (INTERCEPT PHARMACEUTICALS, INC).
The best stock recommendation documented was for ICPT (INTERCEPT PHARMACEUTICALS, INC) at 1/10/2014. The price target of $400 was fulfilled within 3 days with a profit of $45.83 (10.28%) receiving and performance score of 34.27.
Average potential price target upside
Currently, out of the existing stock ratings of Jonathan Eckard - 2331 which are a Buy (85.98%), 380 which are a Hold (14.02%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
28
$14.17 (102.46%)
26
22 days ago
1/15 (6.67%)
$26.32 (67.59%)
90
Hold
18
$4.17 (30.15%)
17
25 days ago
5/7 (71.43%)
$0.92 (20.26%)
104
Buy
26
$12.17 (88.00%)
22
25 days ago
0/6 (0%)
$20.14 (56.82%)
Hold
19
$5.17 (37.38%)
18
25 days ago
7/19 (36.84%)
$21.85 (29.41%)
15
Hold
14
$0.17 (1.23%)
16
4 months 12 days ago
2/2 (100%)
$-0.97 (-6.13%)
32
